| As Gilead Sciences gears up to launch filgotinib, the JAK inhibitor it has under FDA review in rheumatoid arthritis, it knows full well it’s prepping for entry into a crowded market. But it’s got three priorities in mind for the launch—and it thinks those tactics will help set the drug apart from numerous rivals. |
